tbuckley/cabot-search huggingface dataset:
DENMARK
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05–02)
Authors: P. Y. Wen, T. Cloughesy, J. Kuhn, K. Lamborn, L. E. Abrey, F. Lieberman, H. I. Robins, J. Wright, M. D. Prados, M. Gilbert
Journal: Journal of Clinical Oncology (2009)

2006 Background: The activity of targeted molecular therapy with single agents has been disappointing in GBM. Combination therapy simultaneously targeting both the PI3k/Akt/mTOR and the MAP kinase pathway may be more effective. Methods: The North American Brain Tumor Consortium conducted a phase I/II study of sorafenib (VEGFR/PDGFR/Raf inhibitor) in combination with temsirolimus (mTOR inhibitor) in recurrent GBM. Eligibility criteria included histologically proven GBM, radiologic progression, &gt; 18 years old, KPS &gt; 60, adequate bone marrow reserve, and organ function. There was no limit on the number of prior relapses for phase I and no more than two prior relapses for phase II. No enzyme-inducing antiepileptic drugs were allowed. Dose-finding used a standard 3 + 3 design with the MTD defined as the dose with DLTs in 1/6 or fewer patients. The primary endpoint for the phase II component was PFS6 (p0 = 15%; p1 = 35%). A 2-stage design was used. If &gt; 4 of the initial 19 patients achieved PFS6, an additional 14 patients would be accrued for a total of 33 patients. Results: In phase I, 13 patients were enrolled. Median age was 50 years (32–59); median prior chemotherapy 1 (1–3). The initial doses were sorafenib 200 mg bid and temsirolimus 25 mg intravenously once weekly. The MTD was 400 mg bid of sorafenib daily combined with 25 mg of temsirolimus weekly. At this dose 1/6 patients had a DLT (grade 3 thrombocytopenia). Other grade 3 or 4 toxicities included transaminitis, hypophosphatemia, fatigue, diarrhea, and hyperlipidemia. Pharmacokinetic data were similar to that for single agent sorafenib and temsirolimus suggesting that there were no significant interaction between the two drugs. In phase II, 19 patients were accrued to stage I. Median age 50 years (24–64); median prior relapses 1 (range 1–2). One patient was found not to have GBM on central review. No patient remained progression free at 6 months, although two patients stopped treatment prior to 26 weeks for other than progression (alternative therapy, cerebral ischemia). As result, the study was terminated and did not proceed to the second stage. Conclusions: The combination of sorafenib and temsirolimus was moderately well-tolerated but did not demonstrate sufficient efficacy in recurrent GBM to warrant further investigation. No significant financial relationships to disclose.
Tetrachlorethane Poisoning
Authors: G. Forbes
Journal: BMJ (1943)

Qliverio, 1938; Bittrich, 1939; Brunner and de Takats,' 1939; Silvers and Leonard, 1940; Lorhan and Lalich, 1940). The initial rise in blood pressure due to the drug may also be excessive, and the bradycardia which it causes has resulted in partial heart-block (Brunner and de Takats, 1939).Paredrine may also pro'duce an excessive rise in blood pressure-e.g., to 250 mm.systolic (Loman et al., 1939; Altschule and Gilman, 1939).It would thus seem that methedrine is the most valuable of the drugs so far tested for counteracting the serious falls in blood pressure that often occur in surgical operations.The 54 cases of' the series under review are summarized in the table below.Summary of Cases showing Effect of Methedrine on Blood Pressure __________ _____________________ -Max.
Contents and editor’s summaries
Authors: V Deenadayalu, E Orinion, N Chalasani, H Yoo, C Stewart, M Reivich, M Lucey, G Gores, J Inadomi, A Fendrick, F Sinicrope, D Nayar, F Khandwala, E Achkar, S Shay, J Richter, G Falk, E Soffer, M Vaezi
Journal: Clinical Gastroenterology and Hepatology (2005)
Tuberculin Conversion
Authors: C. W. Ochs
Journal: JAMA (1967)

<h3>To the Editor:—</h3> Recent studies indicate that previous tuberculin testsmay boost the intensity of the tuberculin reaction in a sensitized person. However, I believe that this effect played a minor role, if any, as a cause of conversion in my study. 1. The average conversion rate for the original crew members was about the same for the new men. Second-strength tuberculin was given only to the men in the original crew who manifested a negative reaction to intermediate-strength tuberculin; it was not given to the new men. The program also required the original crew members to have more intermediate tuberculin tests, in a shorter period of time, than did the new men. It would appear that the previous testing with second-strength tuberculin, and frequent testing with intermediate-strength tuberculin would have had a greater propensity to induce the "booster effect" than would one or two intermediate-strength tuberculin tests, performed three to
Ectopic expression of c-myc fails to overcome downregulation of telomerase activity induced by herbimycin A, but ectopic hTERT expression overcomes it
Authors: M Akiyama, O Yamada, S Akita, M Urashima, J Horiguchi-Yamada, T Ohno, H Mizoguchi, Y Eto, H Yamada
Journal: Leukemia (2000)
The Crippled Hand and Arm. A Monograph on the Various Types of Deformities of the Hand and Arm as a Result from Abnormal Development, Injuries and Diseases, for the Use of the Practitioner and Surgeon.
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Contents
Authors: Pukhraj Rishi, Ekta Rishi, Vishvesh Agarwal, Sridevi Nair, Geetha Iyer, Albert Li, Antonio Capone, Michael Trese, Jonathan Sears, Andres Kychenthal, Irina De La Huerta, Philip Ferrone, Leo Sheck, Wayne Davies, Phillip Moradi, Anthony Frcophth, Neruban Robson, Alki Frcophth, Andrew Liasis, Anthony Frcophth, Michel Fmedsci, Natasha Van Poppelen, Jolanda Vaarwater, Hardeep Mudhar, Karen Sisley, Ian Rennie, Paul Rundle, Tom Brands, Quincy Van Den Bosch, Hanneke Mensink, Annelies De Klein, Emine Kiliç, Hirofumi Sasajima, Kotaro Tsuboi, Hikari Ono, Kenta Murotani, Motohiro Kamei
Journal: Ophthalmology (2018)
Effect of androgen therapy and anemia on serum erythropoietin levels in patients with aplastic anemia and myelodysplastic syndromes
Authors: Josefa Piedras, Guadalupe Hernández, Xavier López‐Karpovitch
Journal: American Journal of Hematology (1998)

Immunoreactive serum erythropoietin (EPO) was measured in anemic and non-anemic patients with acquired non-severe aplastic anemia (AA; n = 22) and myelodysplastic syndromes (MDS; n = 31) receiving or not androgens to examine the effect of androgen therapy and anemia on EPO levels in these disorders. Soluble transferrin receptor (TfR) and absolute reticulocyte count (ARC) were also assayed in order to evaluate erythropoietic activity. AA and MDS patients were stratified for anemia and androgen treatment as follows: 12 untreated anemic patients; 17 anemic patients during androgen therapy; 14 non-anemic patients without any treatment (>1 year); and 10 non-anemic patients on androgen therapy. Although EPO levels in non-anemic patients were significantly higher than in healthy controls (n = 29) no statistically significant differences in Hb and EPO values were found between non-anemic patients receiving or not androgen therapy. In the linear regression analysis between Hb and log EPO concentration, no statistically significant differences in the slopes between untreated and androgen-treated anemic groups nor between both groups and patients with iron deficiency anemia (n = 23) were observed. However, the y intercept (log EPO) of regression line was significantly higher in androgen-treated anemic patients than in the androgen therapy-free anemic group. Serum TfR levels were higher in treated than in untreated anemic patients, whereas ARC was not different between both groups. These data seemingly indicate that (1) androgens at pharmacological doses do not increase serum EPO levels in non-anemic AA and MDS patients, and (2) in patients with AA and MDS, androgen-driven EPO stimulation is appreciably enhanced by anemia. Am. J. Hematol. 57:113–118, 1998. © 1998 Wiley-Liss, Inc.
A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox In Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R2 mri.
Authors: Yoo-Hong Min, Hyeoung Joon Kim, Kyoo-Hyung Lee, Jae Hoon Lee, Hee-Sook Park, Jin Seok Kim, Hyeok Shim, Chu-Myung Seung, Chul Soo Kim, Jooseop Chung, Myung Soo Hyun, Deog-Yeon Jo, Chul Won Jung, Sang Kyun Sohn, Hwi-Joong Yoon, Byung Soo Kim, Young-Don Joo, Chi-Young Park
Journal: Blood (2010)
Identification of nursing home needs
Authors: F. C. Swartz
Journal: JAMA (1966)

The nursing home in the United States has changed, is changing. The changes have not been uniform. In general, there seems to be more of the early type house on the Atlantic seaboard. In the Middle West and Far West the nursing home has become a more sophisticated unit of the health team. Many new structures are built to meet the nursing-home function and are equipped with modern conveniences and safety features. They no longer cater to the aging ill alone. It has been reported that some homes have patients as young as five years of age. The average age of the patients in the nursing homes is in the low 60's, and will soon go lower. The patient load is made up largely of the chronically ill and disabled of all ages. This type institution is not "a road's end" station but a health facility fitting into the medical
Intern Selection
Authors: LAWRENCE P. TREMONTI
Journal: Annals of Internal Medicine (1973)

Letters1 August 1973Intern SelectionLAWRENCE P. TREMONTI, M.D.LAWRENCE P. TREMONTI, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-79-2-277 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: The interview with potential intern candidates has been viewed as a valuable instrument in determining the success of the candidate as a house officer. As more medical schools and graduate programs adopt a pass-fail grading system, reliable criteria and instruments need to be developed for more efficient use of increasingly scarce educational resources.Whether the interview can be relied on for such discrimination was looked at in our own intern-selection process. Each candidate was given a cumulative rating as excellent, good, or satisfactory by two faculty members of the Department of Medicine. This rating was compared with...Reference1. STERKPRYWES VM: Selection methods for medical schools. II. Critical evaluation of a semi-structured interview. Isr J Med Sci 6:126-131, 1970 MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByImproving methods of resident selectionOphthalmology Resident Selection: Current Trends in Selection Criteria and Improving the ProcessRe-engineering the Resident Applicant Selection Process in Ophthalmology: A Literature Review and Recommendations for ImprovementReliability of a Structured Interview Scoring Instrument for a Canadian Postgraduate Emergency Medicine Training ProgramImproving the Validity of Letters of Recommendation: An Investigation of Three Standardized Reference FormsSelection Criteria for Emergency Medicine Residency ApplicantsVideotape interviewing of candidates for an emergency medicine residency programCriteria for Selecting Residents: A ReassessmentAnalysis of selection criteria for medical residentsLevels of Recommendation for Students and Academic Performance in Medical SchoolTHE DEAN'S LETTER OF EVALUATION AS A BASIS FOR THE SELECTION OF MEDICAL STUDENTSHousestaff Evaluation Using Patient Instructors: 1 August 1973Volume 79, Issue 2Page: 277-277KeywordsGraduate medical education Issue Published: 1 August 1973 PDF DownloadLoading ...
For better hip replacement results, surgeon's best friend may be a robot
Authors: M. F. Goldsmith
Journal: JAMA (1992)

"FRUSTRATION" with the standard procedure has led to the development of a new technique for total hip replacement. Instead of the mallet-and-broach approach to preparing sites for cementless joint implantation, two clinicians working with computers have devised what they believe is a better way. Howard A. (Hap) Paul, DVM, University of California (UC), Davis, School of Veterinary Medicine, and William Bargar, MD, UC Davis, School of Medicine and Sutter General Hospital, Sacramento, came up with Robodoc. This surgical robot, an industrial automaton that has been uniquely fitted for its specialjob of milling out the femoral cavity, is the product of Integrated Surgical Systems (ISS) Inc, the company the two researchers have started in Sacramento. Working from input data supplied by another ISS product, the presurgical planning system called Orthodoc, the surgeon-guided robot has produced cavities in cadaver bone with a dimensional accuracy of 0.1mm—up to 40 times more accurate than
Changing Physician Performance
Authors: David A. Davis
Journal: JAMA (1995)

<h3>Objective.</h3> —To review the literature relating to the effectiveness of education strategies designed to change physician performance and health care outcomes. <h3>Data Sources.</h3> —We searched MEDLINE, ERIC, NTIS, the Research and Development Resource Base in Continuing Medical Education, and other relevant data sources from 1975 to 1994, using<i>continuing medical education</i>(CME) and related terms as keywords. We manually searched journals and the bibliographies of other review articles and called on the opinions of recognized experts. <h3>Study Selection.</h3> —We reviewed studies that met the following criteria: randomized controlled trials of education strategies or interventions that objectively assessed physician performance and/or health care outcomes. These intervention strategies included (alone and in combination) educational materials, formal CME activities, outreach visits such as academic detailing, opinion leaders, patient-mediated strategies, audit with feedback, and reminders. Studies were selected only if more than 50% of the subjects were either practicing physicians or medical residents. <h3>Data Extraction.</h3> —We extracted the specialty of the physicians targeted by the interventions and the clinical domain and setting of the trial. We also determined the details of the educational intervention, the extent to which needs or barriers to change had been ascertained prior to the intervention, and the main outcome measure(s). <h3>Data Synthesis.</h3> —We found 99 trials, containing 160 interventions, that met our criteria. Almost two thirds of the interventions (101 of 160) displayed an improvement in at least one major outcome measure: 70% demonstrated a change in physician performance, and 48% of interventions aimed at health care outcomes produced a positive change. Effective change strategies included reminders, patient-mediated interventions, outreach visits, opinion leaders, and multifaceted activities. Audit with feedback and educational materials were less effective, and formal CME conferences or activities, without enabling or practice-reinforcing strategies, had relatively little impact. <h3>Conclusion.</h3> —Widely used CME delivery methods such as conferences have little direct impact on improving professional practice. More effective methods such as systematic practice-based interventions and outreach visits are seldom used by CME providers. (<i>JAMA</i>. 1995;274:700-705)
Drugs for Tobacco Dependence
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TAHITI FROM A MEDICAL STANDPOINT.
Authors: N. SENN
Journal: JAMA (1904)

Very few people who left the schoolroom twenty-five years ago would be able to locate Tahiti, and many of them have even forgotten the name. The children fresh from school recall it in connection with the difficulty they encountered in finding the little dot in the great trackless South Pacific Ocean, surrounded by a group of still smaller islands, called the Society Islands, so named in honor of the Royal Society of London by the famous explorer, Captain Cook. Tahiti is nearly 4,000 miles distant from San Francisco, in a southwesterly direction below the equator, in latitude 17, hence in a latitude similar to that of the Hawaiian Islands, which are situated about the same distance north of the equator. I had heard much of the beauty of this far-off island, and decided to spend my midwinter vacation by paying it a visit. Formerly the passage from San Francisco had
Wrong Side
Journal: JAMA (1980)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MULTI-SEGMENTED FOOT LANDING KINEMATICS IN SUBJECTS WITH CHRONIC ANKLE INSTABILITY
Authors: R De Ridder, T Willems, J Vanrenterghem, M Robinson, T Palmans, P Roosen
Journal: British Journal of Sports Medicine (2014)

Background Chronic ankle instability (CAI) is associated with inadequate control during landing tasks. Joint kinematics have been shown influential in the capacity to accommodate for the incurred high loading. Objective The purpose of this study was to evaluate whether multi-segmented foot kinematics of the impact phase of landing tasks can reveal further control issues in subjects with CAI, copers, and controls. Design Case-control design. Setting All subjects were evaluated in a laboratory setting with a 3D kinematic setup. Participants 96 recreationally active subjects (38 subjects with CAI, 28 copers and 30 controls) were included in the study. Risk factor assessment All subjects performed a vertical drop and side jump landing task. Data were collected using a force plate and a 6-camera opto-electronic system. Main outcome measurements Foot and ankle kinematics were registered using a rigid foot model and the six-segment Ghent Foot Model (GFM), along with vertical ground reaction forces. Group differences were evaluated using Statistical Parametric Mapping and ANOVA with post-hoc Bonferroni correction. Results In general, similar sagittal plane differences were found for vertical drop and side jump. Subjects with CAI and copers exhibited less plantar flexion at touch down. In addition, unlike the coper group, the CAI group demonstrated a stiffer landing pattern (smaller ROM) compared to the control group, leading to higher loading rates. Furthermore, subjects with CAI had a more inverted midfoot position compared to controls during side jump and more midfoot in/eversion ROM than copers during vertical drop. Copers exhibited less plantarflexion/dorsiflexion ROM in the lateral and medial forefoot for both conditions. Conclusions Subjects with CAI displayed an altered, stiffer kinematic landing strategy and related alterations in landing kinetics, which might predispose them for episodes of giving way and actual ankle sprain events.